Welcome Guest
Home > Clinical Breast Cancer > Volume 7 |  Issue 7 > Article Abstract

Abstract
Back to TOC
References
X

Note:- Read as Author : Article Title : Source : Year : Publisher

    1.  Anonymous. Part VII. Breast. In: Green FL, Page DL, Fleming ID,et al, eds. 6th ed. New York, NY: Springer. AJCC Cancer Staging Handbook ; 2002:225-281.
    2.  Giordano SH. Update on locally advanced breast cancer. Oncologist 2003; 8:521-530.
    3.  Hortobagyi GN, Singletary SE, Strom EA, et al. Locally advanced breast cancer. In: Harris JA, eds. Diseases of the Breast 3rd ed. Philadelphia, PA: Williams and Wilkins;. 2004:951-969.
    4.  Hortobagyi G, Singletary SE, Strom EA, et al. Treatment of locally advanced breast cancer. In: Harris JA, ed. Diseases of the Breast 2nd ed. Philadelphia, PA: Williams and Wilkins. 2000:645-660.
    5.  Brown A, Fischer B, Fisher B, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15:2483-2493.
    6.  Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathological tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17:460-469.
    7.  Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004; 10:6622-6628.
    8.  Faneyte IF, Peterse JL, Schrama JG, et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003; 88:406-412.
    9.  Eisen MB, Perou CM, Sorlie T, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
    10.  Burstein HJ. The distinctive nature of HER2-positive breast cancer. N Engl J Med 2005; 353:1652-1654.
    11.  Carey LA, Livasy CA, Perou CM, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer study. JAMA 2006; 295:2492-2502.
    12.  The World Health Organization. The World Health Organization histological typing of breast tumors-second edition. Am J Clin Pathol 1982; 78:806-816.
    13.  Allen C, Carter CL, Henson DE, et al. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63:181-187.
    14.  Buchholz TA, Hunt KK, Whitman GJ, et al. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 2003; 98:1150-1160.
    15.  Buchholz TA, Katz A, Strom EA, et al. Pathologic tumor size and lymph node status predict for different rates of locorregional recurrences after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2002; 53:880-888.
    16.  King RJ, Stewart JF, Winter PJ, et al. Oestrogen receptors, clinical features and prognosis in stage III breast cancer. Eur J Cancer Clin Oncol 1982; 18:1315-1320.
    17.  Broglio K, Guarneri V, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and others factors. J Clin Oncol 2006; 24:1037-1043.
    18.  Parker J, Sorlie T, Tibshirani R, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100:8418-8423.
    19.  McShane LM, Neo SY, Sotiriou C, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003; 100:10393-10398.
    20.  Fiche M, Penault-Llorca F, Sastre X, et al. Pathological response to neoadjuvant chemotherapy (CT): final results of a prospective randomized trial of 4AT vs 4AC as induction therapy in patients with operable breast cancer using Sataloff classification. Breast Cancer Res Treat 1999; 57:67-67.
    21.  Heys S, Heys SD, Hutcheon A, Hutcheon AW, Smith IC, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20:1456-1466.
    22.  Buzdar AU, Francis D, Ibrahim NK, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-posi-tive operable breast cancer. J Clin Oncol 2005; 23:1-10.
    23.  Anderson S, Bear HD, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21:4165-4174.
E-mail this article
X

Fields marked with an asterisk * are mandatory.

* Your Name:
* Your Email:
* Friend's Name:
* Friend's Email:
Message:
 
Send CC to self
 
 
Add to Favorites
X
  • Volume 7
  •  Issue 7
    • Publication Date: April 2007


Analysis of the Pathologic Response to Primary Chemotherapy in Patients with Locally Advanced Breast Cancer Grouped According to Estrogen Receptor, Progesterone Receptor, and HER2 Status


Luis A. Fernández-Morales, Miquel A. Segu¡, Xavier Andreu, Elsa Dalmau, Amparo Sáez, Carles Pericay, Cristina Santos, Jesús Montesinos, Enrique Gallardo, Angels Arcusa, Eugeni Saigí

Purpose: In clinical practice, it is possible to classify breast tumors according to estrogen receptor (ER), progesterone receptor (PgR), and HER2 overexpression: ER negative, PgR negative, and HER2 overexpressing; ER negative, PgR negative, and HER2 negative; ER positive, PgR positive, and HER2 negative; ER positive, PgR positive, and HER2 overexpressing; and the less frequent remaining 4 combinations. The aim of this study was to determine the percentage of pathologic complete response (pCR) in patients with locally advanced breast cancer (LABC) treated with neoadjuvant or primary chemotherapy with anthracyclines and taxanes grouped according to ER, PgR, and HER2 status. Patients and Methods: Patients with LABC treated with primary chemotherapy including anthracyclines and taxanes were grouped according to ER, PgR, and HER2 status; pCR rates were analyzed using the χ2 test; and correlations with a P value of <= 0.05 were considered statistically significant. Results: A total of 103 patients were treated. Only 100 patients were included for the analysis of pCR. Eighteen patients exhibited pCR. The pCR rate for each subgroup was as follows: 39.1% (9 of 23) had ER-negative, PgR-negative, and HER2-negative disease (P < 0.01); 35.7% (5 of 14) had ER-negative, PgR-negative, and HER2-overexpressing disease; 33.3% (3 of 9) had ER-positive, PgR-positive, and HER2-overexpressing disease; and 2.8% (1 of 36) had ER-positive, PgR-positive, and HER2-negative disease (P < 0.01). Conclusion: In patients with LABC, grouping breast tumors according to ER, PgR, and HER2 status can help predict pCR to primary chemotherapy.

Key words: Anthracyclines, Basal-like subgroups, Hormone receptor, Taxanes, Trastuzumab


  1. https://www.ceteresopolitano.org/
  2. https://www.crossingstoronto.com/
  3. https://www.jediism.org/
  4. https://www.badenumc.org/
  5. https://www.johnsevierchapter.org/
  6. https://www.trinitychapelmn.org/
  7. https://www.photogearnews.com/
  8. https://www.alz-nova.org/
  9. https://www.cigjournals.com/
  10. https://summa-edu.com/
  11. https://cpawilmingtonnc.org/
  12. https://bimometals.com/
  13. https://sosenvironmental.com/
  14. https://thefriary.org/
  15. https://post5theatre.org/
  1. KELUARAN SGP
  2. TOGEL